News Release

Nirmatrelvir-ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection

JAMA Internal Medicine

Peer-Reviewed Publication

JAMA Network

About The Study: The results of this randomized clinical trial showed that a 15-day course of nirmatrelvir-ritonavir in a population of patients with postacute sequelae of SARS-CoV-2 infection (PASC) was generally safe but did not demonstrate a significant benefit for improving select PASC symptoms in a mostly vaccinated cohort with protracted symptom duration. Further studies are needed to determine the role of antivirals in the treatment of PASC. 

Corresponding Author: To contact the corresponding authors, email Linda N. Geng, M.D., Ph.D. (geng@stanford.edu) and Upinder Singh, M.D. (usingh@stanford.edu).

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamainternmed.2024.2007)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being presented at the Demystifying Long COVID North American Conference 2024. 

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.2007?guestAccessKey=face4b31-1b6e-498a-a147-cf6a9dee6986&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060724


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.